InMed Pharmaceuticals (INM) Common Equity (2019 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Common Equity of $6.9 million for Q1 2026, down 1.85% year-over-year from $7.0 million in Q1 2025, and down 28.12% quarter-over-quarter from $9.6 million in Q4 2025.
InMed Pharmaceuticals (INM) Common Equity (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- In Q1 2026, Common Equity fell 1.85% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (down 1.85% YoY), while the FY2025 annual figure was $13.4 million, up 45.93% from the prior year.
- Common Equity for Q1 2026 stood at $6.9 million, down from $9.6 million in the prior quarter.
- The five-year high for Common Equity was $14.3 million in Q4 2022, with the low at -$9.6 million in Q3 2023.
- The 5-year median for Common Equity is $10.9 million (2022), against an average of $9.2 million.
- The sharpest annual moves came in 2023 and 2024: Common Equity plunged 187.01% in 2023, then jumped 187.65% in 2024.
- InMed Pharmaceuticals' Common Equity stood at $14.3 million in 2022, then declined by 10.9% to $12.8 million in 2023, then slumped by 51.6% to $6.2 million in 2024, then surged by 55.09% to $9.6 million in 2025, then decreased by 28.12% to $6.9 million in 2026.
- Business Quant data shows INM's Common Equity at $6.9 million in Q1 2026, $9.6 million in Q4 2025, and $11.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 4.05 Bn |
| 10 | InMed Pharmaceuticals | 6.44 Mn | 1.20 Mn | - | 6.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.89 Mn |
| Dec 31, 2025 | 9.59 Mn |
| Sep 30, 2025 | 11.59 Mn |
| Jun 30, 2025 | 13.43 Mn |
| Mar 31, 2025 | 7.02 Mn |
| Dec 31, 2024 | 6.18 Mn |
| Sep 30, 2024 | 8.40 Mn |
| Jun 30, 2024 | 9.21 Mn |
| Mar 31, 2024 | 11.10 Mn |
| Dec 31, 2023 | 12.77 Mn |
| Sep 30, 2023 | -9.58 Mn |
| Jun 30, 2023 | 12.09 Mn |
| Mar 31, 2023 | 12.39 Mn |
| Dec 31, 2022 | 14.34 Mn |
| Sep 30, 2022 | 11.01 Mn |
| Jun 30, 2022 | 9.08 Mn |
| Mar 31, 2022 | 10.89 Mn |
| Dec 31, 2021 | 14.17 Mn |
| Sep 30, 2021 | 15.22 Mn |
| Jun 30, 2021 | 7.38 Mn |